Healthcare / BiotechnologyNasdaqCM
$1.74
+0.06 (+3.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-16.7M · quality 71.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$72M
P/E
N/A
•EV/EBITDA
N/A
•ROE
3.1%
↑Gross Margin
N/A
•Debt/Equity
-0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
19.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-1.0M · FCF $-19.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $1.4M |
| Net Income | $-1.0M | $-1.0M | $-11.1M | $-21.0M | $-33.3M |
| EBITDA | $-8.9M | $-8.9M | $-8.5M | $-14.8M | $-35.9M |
| EPS | -0.02 | -0.02 | -0.28 | -0.54 | -0.85 |
| Operating Margin | — | — | — | — | -2756.4% |
| Net Margin | — | — | — | — | -2463.3% |
| Balance Sheet | |||||
| Debt/Equity | -0.01 | -0.01 | -0.02 | -0.03 | -0.83 |
| Current Ratio | 1.09 | 1.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-19.8M | $-19.8M | $-16.7M | $-16.6M | $-28.2M |
| Returns | |||||
| ROE | 3.1% | 3.1% | 33.8% | 78.4% | 556.6% |
| Growth & Yield | |||||
| EPS Growth | 92.9% | 92.9% | 48.1% | 36.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.28 → -0.02
Residual
-0.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.